• Skip to content
  • Accessibility help
Skip to content
Sign in
  • Guidance
  • Skip Standards and indicators submenu

    Quality standards

    Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.

    View our quality standards

    • How to use our quality standards
    • The timeline for developing quality standards
    • Help us develop quality standards
    • Selecting and prioritising quality standards topics
    • About quality standards

    Indicators

    Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.

    View list of indicators

    • Learn about the committee that develops indicators
    • About indicators
  • Skip Life sciences submenu

    Life Sciences

    We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.

    View life sciences

    Get support from NICE

    NICE Advice service

    Trusted, unrivalled expertise.

    Make an enquiry

    Contact us to discuss your requirements.

    Innovative Licensing and Access Pathway (ILAP)

    Streamlining patient access to safe, financially sustainable and innovative medicines.

    Learn how we evaluate technologies

    Health technology evaluation and topic selection manuals

    Updated manuals for methods, processes and topic selection.

    Digital health technologies

    Accelerating our efforts to deliver innovation to the health and care system.

    Evidence standards framework

    Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.

    Our guidance programmes

    Ensuring new technologies are clinically effective and offer economic value.

    Register your product

    Non-pharmaceutical

    NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.

    Pharmaceutical

    UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.

    Find published and proposed evaluations

    Diagnostics

    Guidance on measurements and tests used to evaluate a patient's condition.

    Medical technologies

    Guidance on medical technologies put forward to NICE by manufacturers.

    Technology appraisals

    Guidance on new and existing medicines and treatments in the NHS.

    Highly specialised technologies

    Guidance on the use of highly specialised medicines and treatments.

  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Skip About submenu

    About

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

    Explore about

    Our programmes

    Learn about the information we produce.

    • Guidance
    • Advice
    • Quality standards
    • Indicators
    • Digital health
    • Topic selection

    Get involved

    • Understand how decisions are made:

      Attend a committee meeting
    • Comment on draft guidance:

      Guidance in consultation
    • Be part of a guidance committee:

      Join a committee
    • Help develop our products:

      Register as a stakeholder
    • Putting you at the heart of our work:

      Public involvement

    What we do

    • Social care
    • Life sciences
    • NICE international
    • Patient safety
    • Shared decision making
    • View all What we do

    Into practice

    • Social care quick guides
    • Measuring the use of NICE guidance
    • Resource planner
    • View all Into practice

    Who we are

    • The board
    • The NICE strategy 2021 to 2026
    • Corporate publications
    • View all Who we are

    • Contact us
    • Jobs

My account

  • Consultation responses
  • Sign in

You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Eye conditions

Serious eye disorders

  • Quality standard
  • Reference number: QS180
  • Published:  12 February 2019
  • Quality standard
  • Tools and resources
  • History
Download (PDF)
  • Overview
  • Quality statements
  • Quality statement 1: Referral – chronic open angle glaucoma and related conditions
  • Quality statement 2: Referral for cataract surgery
  • Quality statement 3: Treatment – late age-related macular degeneration (wet active)
  • Quality statement 4: Monitoring late age-related macular degeneration (wet active)
  • Quality statement 5: Reassessment – chronic open angle glaucoma or related conditions
  • Quality statement 6: Certificate of vision impairment
  • Update information
  • About this quality standard

On this page

  1. Quality statement
  2. Rationale
  3. Quality measures
  4. What the quality statement means for different audiences
  5. Source guidance
  6. Definitions of terms used in this quality statement

Quality statement 1: Referral – chronic open angle glaucoma and related conditions

Quality statement

Adults with signs of possible glaucoma or related conditions on a routine sight test have additional tests before they are referred for a diagnosis.

Rationale

Accurate diagnosis of chronic open angle glaucoma (COAG) or related conditions is important because they can lead to irreversible damage to the optic nerve and sight loss. As well as the routine sight test, additional tests are needed for people with possible glaucoma to support more accurate referrals for further investigation and diagnosis. They ensure that adults with COAG or related conditions have prompt diagnosis and treatment and people who do not need referral avoid unnecessary investigations.

Quality measures

The following measures can be used to assess the quality of care or service provision specified in the statement. They are examples of how the statement can be measured, and can be adapted and used flexibly.

Structure

a) Evidence of the availability of equipment for performing the additional tests needed before referral for further investigation and diagnosis of COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, service specifications.

b) Evidence of the availability of staff trained to perform the additional tests needed before referral for further investigation and diagnosis of COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, staff rotas and staff training records.

Process

Proportion of adults with signs of possible glaucoma on a routine sight test who had additional tests before referral for further investigation and diagnosis of COAG or related conditions.

Numerator – the number in the denominator who had additional tests before referral for further investigation and diagnosis of COAG or related conditions.

Denominator – the number of adults with signs of possible glaucoma on a routine sight test referred for further investigation and diagnosis of COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, patient records and referral records.

Outcome

Rates of false-positive referrals for further investigation and diagnosis of COAG or related conditions.

Data source: No routinely collected national data for this measure has been identified. Data can be collected from information recorded locally by healthcare professionals and provider organisations, for example, patient records and referral records.

What the quality statement means for different audiences

Service providers (such as community optometry services) ensure that equipment, staff training and local referral pathways support adults with possible glaucoma to have additional tests after the routine sight test and before referral for further investigation and diagnosis of COAG or related conditions.

Healthcare professionals (such as community optometrists) ensure additional tests are performed when signs of possible glaucoma are detected on a routine sight test and refer on the basis of these results.

Commissioners (clinical commissioning groups and NHS England) ensure that services have agreed protocols and ensure service availability to support accurate referral into hospital eye services for adults with possible COAG or related conditions. They monitor referrals.

Adults with possible glaucoma have a range of tests after the routine sight test and before they are referred to hospital eye services. This means that only people needing further investigations are referred, which may reduce waiting times.

Source guidance

Glaucoma: diagnosis and management. NICE guideline NG81 (2017, updated 2022), recommendation 1.1.1

Definitions of terms used in this quality statement

Possible glaucoma or related conditions

Signs of possible glaucoma or related conditions include:

  • a glaucomatous-type visual field defect

  • visible structural damage to the optic nerve head

  • an intraocular pressure of 24 mmHg or more.

[Adapted from NICE's guideline on glaucoma, recommendation 1.1.5; and expert opinion]

Additional tests

If a routine sight test suggests signs of possible glaucoma, all of the following additional tests should be undertaken before referral:

  • central visual field assessment using standard automated perimetry (full threshold or supra‑threshold)

  • optic nerve assessment and fundus examination using stereoscopic slit lamp biomicroscopy (with pupil dilatation if necessary), and optical coherence tomography (OCT) or optic nerve head image if available

  • intraocular pressure measurement using Goldmann-type applanation tonometry

  • peripheral anterior chamber configuration and depth assessments using gonioscopy or, if not available or the person prefers, the van Herick test or OCT.

[NICE's guideline on glaucoma, recommendation 1.1.1]


Next page Quality statement 2: Referral for cataract surgery Previous page Quality statements
  • Guidance
  • Standards and indicators
  • Life sciences
  • British National Formulary (BNF)
  • British National Formulary for Children (BNFC)
  • Clinical Knowledge Summaries (CKS)
  • Knowledge resources
  • About NICE
  • Into practice
  • Get involved with NICE
  • Jobs
  • News
  • Newsletters and alerts
  • Contact us
  • Leave feedback
  • Reusing our content
  • NICE UK Open Content Licence
  • Syndicate our content
  • Events
  • Facebook
  • X
  • YouTube
  • LinkedIn
  • Accessibility
  • Freedom of information
  • Glossary
  • Terms and conditions
  • Privacy notice
  • Cookies

© NICE 2025. All rights reserved. Subject to Notice of rights.